Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Amgen's study of the drug Maritide in people with Type 2 diabetes showed noteworthy reductions in HbA1c and weight. The ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

President Trump’s self-branded attempt to cut drug prices, TrumpRx, is set to launch within weeks, offering a novel pathway ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

Thousand Oaks-based Amgen Inc. on Jan. 6 announced it has acquired Oxford, U.K.-based Dark Blue Therapeutics Ltd., a ...

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.

We’re launching the Business Times’ special report calendar with a shoutout to Amgen, whose decision to build a $600 million research center on its Thousand Oaks campus is our Deal of the Year. We’ll ...